Ascendis Pharma A/S
- Last sale
- Nov 12, 2026 · +2.89%
- Market cap
- $16.52B
- 61.98M shares
- Filings
- 802
FY 2025+98.0% FY25 yoy
FY 2025N/M FY25 yoy
FY 2025N/M FY25 yoy
Q3 2024derivedN/M FY23 yoy
FY 2025N/M FY25 yoy
FY 2025+10.1% FY25 yoy
- $16.52B
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | €720,132,000 | reported | |
| FY 2024 | 2024-12-31 | €363,641,000 | reported | |
| FY 2023 | 2023-12-31 | €266,718,000 | reported | |
| FY 2022 | 2022-12-31 | €51,174,000 | reported | |
| FY 2021 | 2021-12-31 | €7,778,000 | reported | |
| FY 2020 | 2020-12-31 | €6,953,000 | reported | |
| FY 2019 | 2019-12-31 | €13,375,000 | reported | |
| FY 2018 | 2018-12-31 | €10,581,000 | reported | |
| FY 2017 | 2017-12-31 | €1,530,000 | reported | |
| FY 2016 | 2016-12-31 | €4,606,000 | reported | |
| FY 2015 | 2015-12-31 | €8,118,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | €17.40M | €17.40M | — | 61.98M sh | +2.1% | — |
| FY2024 | — | €0.00 | €0.00 | — | 60.69M sh | +5.2% | — |
| FY2023 | — | €0.00 | €0.00 | — | 57.71M sh | +1.0% | — |
| FY2022 | — | €105.31M | €105.31M | — | 57.15M sh | +0.4% | — |
| FY2021 | — | €21.61M | €21.61M | — | 56.94M sh | +5.9% | — |
Segments
Geography
LineFY2025ShareChange
USA€546.39M76%+134.4%
Europe€120.95M17%−1.9%
Rest of World€52.80M7.3%+634.3%
Denmark€12.90M1.8%−86.5%
Asia———
China———
North America———
Total€720.13M
Pharmaceutical preparations
Ascendis Pharma A/S is the 23rd largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
VTRSViatris Inc$14.3B3.0%24.6%$23.7BALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0B
ASNDAscendis Pharma A/S (this company)———$16.5B
JAZZJazz Pharmaceuticals plc$4.3B4.9%8.3%$15.4BKNSAKiniksa Pharmaceuticals International, plc$677.6M60.1%8.7%$15.1BBBIOBridgeBio Pharma, Inc.$502.1M126.3%144.4%$14.6BELANElanco Animal Health Inc$4.7B6.2%4.9%$13.3BRDYDr Reddys Laboratories Ltd———$12.3BSMMTSummit Therapeutics Inc.———$12.1BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Ascendis Pharma A/S · CIK 1612042 · Engraved from SEC EDGAR